

Market Round-up

V28 – 14th December, 2018

General Market News:

- **IPHA President Aidan Lynch** says the Irish Government is no more constrained than any other European government and there is no justification for reimbursement approval delays.
[LINK](#)
- **GSK** have acquired **TESARO**, an oncology-focused company based in the US for approximately \$5.1bn.
[LINK](#)
- EIB provided €30 million to biotech company **Nuritas**, for artificial intelligence and DNA analysis
[LINK](#)
- **Novartis**' **Kymriah** shows 'strong efficacy', 'durable response' in new analysis
[LINK](#)
- Real-world data show **Novartis** drug **Revolade**® improves outcomes for ITP patients compared to other second-line therapies
[LINK](#)
- High-cost **Gilead** cell therapy proves durable for some **lymphoma** patients
[LINK](#)
- **Pfizer** are expected to announce a dividend increase this week. The company has boosted its dividend each of the last eight years.
[LINK](#)
- **Amgen** presents at 60th American Society of Hematology (ASH) annual meeting presentation
[LINK](#)
- **Pfizer** has announced the appointment of **Ben Osborn** as managing director in the UK, taking over from Erik Nordkamp, who will now become general manager UK and cluster lead Europe.
[LINK](#)
- Launch of largest ever UK lung cancer screening study
[LINK](#)
- **Circassia Pharmaceuticals** is exercising an option to acquire the full US commercial rights to **AstraZeneca's Tudorza**.
[LINK](#)
- **Pfizer** still unable to get on top of problems at **Hospira** injectables plant
[LINK](#)
- **J&J** says its psoriasis drug **Tremfya** is superior to **Novartis** treatment in study
[LINK](#)
- The Government may be prepared to pay a salary of about €300,000 as it seeks to find a **chief executive** to run the Health Service Executive .
[LINK](#)

Biologics / Biosimilars:

- **Amgen** and **Entera Bio Ltd.** have announced that they have entered into a research collaboration and license agreement to develop orally administered formulations of biologic drugs.
[LINK](#)
- **Genentech** (a subsidiary of **Roche**) and **Pfizer** reach settlement over **Genentech's** reference trastuzumab product, **Herceptin**
[LINK](#)
- **Novartis** prepares to defend **Omalizumab** market as potential biosimilars advance
[LINK](#)

NCPE Drug Updates

- A full HTA was recommended on December 11th for **Takenda's Brigatinib** (Alunbrig ®)
[LINK](#)
- A full HTA was not recommended for **BioQ Pharma / Galen's Ropivacaine Readyfusor**. Further, the NCPE recommends that **Ropivacaine Readyfusor** not be considered for reimbursement at the submitted price.
[LINK](#)
- A full HTA was not recommended for **Novartis's Ozenoxacin** (Dubine®). Further, the NCPE recommends that **Ozenoxacin** (Dubine®) not be considered for reimbursement at the submitted price.
[LINK](#)
- Full pharmacoeconomic assessment was recommended on December 6th for **AstraZeneca's Lesinurad** (Zurampic®)
[LINK](#)
- On December 7th, the NCPE recommended a full HTA to assess the clinical effectiveness and cost effectiveness of **MSD's Pembrolizumab (Keytruda®)** for Adjuvant melanoma
[LINK](#)

Drug Approvals/Filings:

- **Shire** has announced that the EC has approved its hereditary angioedema (HAE) drug **Takhzyro**
[LINK](#).
- **Shire's Adynovate** has been approved in Canada for treating **Hemophilia** in patients younger than 12
[LINK](#)
- **Amgen** filed nearly 3 times more patents on **Enbrel** in US than EU or Japan, report finds
[LINK](#)
- **Novartis** receives European approval for self-administration of **Xolair**
[LINK](#)

Brexit:

- Pharmacy should take Brexit lead and do what they can to protect the interests of patients
[LINK](#)
- Pharma calls for more detail on plan for post **Brexit** medicine access to ensure continuation of medicine supply.
[LINK](#)